Table 4 Overview of results of comparative treatment analysis including main data characteristics

Active component

Marbofloxacin

Enrofloxacin

0.9% saline

Number of animals

12

12

12

Average body weight of the animals

12.0 ± 2.4

12.6 ± 2.9

12.1 ± 2.4

Intention to treat population (number of animals)

11

12

11

Number of animals included for primary efficacy criterion analysis

10

12

10

Number of animals included for secondary efficacy criteria analyses

11

12

11

Number of removals due to euthanasia criteria (mortality %)

1 (8.3%)

0 (0.0%)

8 (66.7%)

Lung Lesion Score^a

mean

Min-Max

3.9 ± 4.1

0.0–14.9

6.0 ± 5.1

0.5–20.1

21.1 ± 7.7

10.2–35.0

Number of animals bacteriologically cured^b (%)

11 (100%)

1 (91.7%)

0 (0%)

Numbers of animals clinically cured^b (%)

10 (90.9%)

10 (83.3%)

1 (9.1%)

Daily weight gain^b: infection to removal (kg)

1.81 ± 0.774

1.83 ± 0.606

0.69 ± 1.335